Developments FDA grants RMAT designation to Allogene’s ALLO-316 for patients with RCC Allogene Therapeutics (NASDAQ:ALLO) has announced that the FDA granted Regenerative Medicine Advanced Therapy (RMAT) designation to its ALLO-316 for treating adult patients with CD70-positive advanced or metastatic... October 29, 2024